– ARTHEx Biotech announces its sponsorship and participation in the Spanish Meeting on Oligonucleotide Therapies (SMOT III)
VALENCIA, Spain, October 24, 2023 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on the development of innovative medicines through the modulation of microRNAs, today announced that it will participate in the Spanish Oligonucleotide Therapeutics Meeting (SMOT III), which will take place on October 26 and 27, 2023 at the Faculty of Pharmacy of the University of Valencia. SMOT III has the support of the Conselleria D’Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.
SMOT III is a cutting-edge event that brings together experts, researchers, entrepreneurs, investors and companies in the field of therapeutic oligonucleotides to promote collaboration, knowledge exchange and the latest advances in this exciting field.
ARTHEx and the biomedical research center of Hospital La Fe (IIS La Fe) organize the event. In addition, the CSO and co-founder of ARTHEx, Beatriz Llamusi, is one of the welcome and closing speakers of the event and will chair some sessions of the meeting.
ARTHEx presentations during SMOT III are detailed below:
Date/time: Thursday, October 26, 2023, 9:30 a.m. – 11:00 a.m. CETPresenter: Beatriz Llamusi, scientific manager and co-founder of ARTHEx BiotechSession title: Successful stories: Oligonucleotide therapeutics entrepreneurship projectsTitle: “How to turn a therapeutic project into a clinical stage company”
Date/time: Friday, October 27, 2023, 2:00 p.m. – 4:00 p.m. CETPresenter: Nuria Barquero, head of toxicology at ARTHEx BiotechSession title: Preclinical tools and developmentTitle: “Preclinical development of antimiR ATX-01”
You will find more information about SMOT III, including registration details and the program, here: link.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on the development of innovative medicines through the modulation of microRNAs. The company’s lead investigational compound, ATX-01, is advancing toward clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. ARTHEx is also advancing its internal discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically driven diseases such as T1D. The company’s headquarters are in Valencia (Spain).
For more information visit www.arthexbiotech.com and contact us through LinkedIn.
Company contact
Frédéric LegrosExecutive President and CEOflegros@arthexbiotech.com 33679495790
Investor and Media ContactAmy ConradJuniper Pointamy@juniper-point.com 1 858-366-3243
Logo – https://mma.prnewswire.com/media/2068054…
View original content: https://www.prnewswire.com/es/comunicados-de-prensa/arthex-biotech-anuncia-su-patrocinio-y-participacion-en-la-smot-iii-301965874.html
